Skip to main content

The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen’s impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.:

Source: Neurology Read More